pharmadog

Jobs

department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

News

when

Latest
Archive

by source

All Sources
Sources Page

Companies

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

Calendar

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

made by humans and a good dog

home
jobs
news
cal
search

Aprea Therapeutics, Inc. ($APRE) · pharmadog

PUBLIC COMPANY

save

$APREAprea Therapeutics, Inc.

Doylestown, PA, USupdated 1mo ago

SEC EDGAR ↗Yahoo Finance ↗

community read0 votes

pipeline

marketed

phase 3

catalysts ytd

approvals ytd

recalls ytd

Pipeline(2)

pipeline depth2 products

1Phase 11Phase 2

Upcoming

no upcoming catalysts on record

Recent

🕒

(90d)

nothing in the last 90 days

view all catalysts →

🐶 Hiring Signal

No open roles indexed yet — view Aprea Therapeutics, Inc. jobs →

News

no news has mentioned this company yet

identifiers

ticker

$APRE

SEC CIK

0001781983

country

source

sec_tickers

top tags

Oncology2 Breast Cancer1

mentioned in

0news items

entity-linker matched

$APRE

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

Insider activity

source: SEC Form 4

open-market buys + sells

Mar 31, 26BUYPeters Richard· 123,915 sh @ $0.81$100K↗
Mar 31, 26BUYHamill John P.· SrVP/CFO/Prin Fin & Acct Ofcr30,978 sh @ $0.81$25K↗
Mar 31, 26BUYHamill John P.· SrVP/CFO/Prin Fin & Acct Ofcr30,978 sh @ $——↗
Mar 31, 26BUYPeters Richard· 123,915 sh @ $——↗
Jan 30, 26BUYGilad Oren· President/CEO28,100 sh @ $0.89$25K↗
Jan 30, 26BUYHamill John P.· SrVP/CFO/Prin Fin & Acct Ofcr5,700 sh @ $0.89$5K↗
Jan 30, 26BUYHamill John P.· SrVP/CFO/Prin Fin & Acct Ofcr5,700 sh @ $——↗
Jan 30, 26BUYGilad Oren· President/CEO28,100 sh @ $——↗

routine RSU / option mechanics (4)

Mar 12, 26grantHamill John P. · SrVP/CFO/Prin Fin & Acct Ofcr10,095 sh
Mar 12, 26grantGilad Oren · President/CEO20,175 sh
Mar 12, 26grantGilad Oren · President/CEO80,700 sh
Mar 12, 26grantHamill John P. · SrVP/CFO/Prin Fin & Acct Ofcr40,380 sh

Data sources

SEC EDGAR

last refreshed 49m ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

Active trials

phase1Study of APR-1051 in Patients With Advanced Solid Tumorsrecruitingn=90
phase2Study Of ATRN-119 In Patients With Advanced Solid Tumorsactive not recruitingn=132
phase2Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignanciescompletedn=40
phase3APR-246 & Azacitidine for the Treatment of TP53 Mutant Myelodysplastic Syndromes (MDS)completedn=154
phase2p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin Combination Chemotherapy With or Without APR-246

completed

n=247

phase1APR-246 in Combination With Venetoclax and Azacitidine in TP53-Mutant Myeloid Malignanciescompletedn=51

phase2p53 Activation in Platinum-Resistant High Grade Serous Ovarian Cancer, a Study of PLD With APR-246completedn=36

phase2APR-246 in Combination With Acalabrutinib or Venetoclax Based Therapy in Subjects With R/R Non Hodgkin Lymphomas (NHL)terminatedn=1

more trials →

$APREAprea Therapeutics, Inc.

Pipeline(2)

📅 Upcoming

Recent

News

comments(0)

Insider activity

open-market buys + sells

Active trials

Upcoming